European Commission Approves TEVIMBRA® for First-Line Treatment of Esophageal and Gastric Cancers

 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, announced ...

November 28, 2024 | Thursday | News
Novartis Announces European Commission Approval of Kisqali® (ribociclib) for Adjuvant Treatment of High-Risk HR+/HER2- Early Breast Cancer

Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the ad...

November 28, 2024 | Thursday | News
AstraZeneca’s Truqap Combination Shows Significant Benefit in PTEN-Deficient Prostate Cancer in CAPItello-281 Phase III Trial

Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with ...

November 26, 2024 | Tuesday | News
SCG Cell Thearapy Presents Promising Phase 1 Data for SCG101, a First-in-Class HBV-Specific TCR-T Therapy

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associa...

November 25, 2024 | Monday | News
Hanmi Pharmaceutical Showcases Promising Clinical Progress of BH3120 at SITC 2024 Conference

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical...

November 25, 2024 | Monday | News
HUTCHMED and Takeda Launch FRUZAQLA® for Colorectal Cancer in Japan

Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — Milestone payment to be made to HUTCHMED fro...

November 22, 2024 | Friday | News
Jazz Pharmaceuticals Secures FDA Approval for Ziihera, First Dual HER2-Targeted Therapy for Advanced Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zan...

November 21, 2024 | Thursday | News
AstraZeneca’s Tagrisso (osimertinib) Recommended for EU Approval in Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...

November 19, 2024 | Tuesday | News
Exact Sciences Partners with Carlos Ponce to Raise Awareness of Colon Cancer in Hispanic Community

Exact Sciences, a leading provider of cancer screening and diagnostic tests, is proud to announce a new partnership with award-winning Hispanic actor, TV p...

November 19, 2024 | Tuesday | News
EMA Committee Recommends Approval of Opdivo® + Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

 Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

November 18, 2024 | Monday | News
BioNTech Acquires Biotheus to Strengthen Oncology Pipeline with Bispecific Antibody Asset BNT327/PM8002

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) announced the signing of a definitive agreement for...

November 14, 2024 | Thursday | News
TAE Life Sciences and Stella Pharma Announce Exclusive Collaboration to Expand BNCT Therapy in the U.S. and Europe

TAE Life Sciences (TLS), a leader in boron neutron capture therapy (BNCT) technology, and Stella Pharma, the pioneering developer of the boronophenylalan...

November 14, 2024 | Thursday | News
Exact Sciences to Present Key Findings on Multi-Cancer Early Detection Test at AACR Conference in San Diego

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant adv...

November 14, 2024 | Thursday | News
Ontada and Datavant Forge Strategic Collaboration to Accelerate Oncology Innovation Through Real-World Data Integration

 Ontada®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, has ...

November 13, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close